CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Allan Reine, M.D., as the Company’s Chief Financial Officer, effective January 17, 2024.

马萨诸塞州剑桥市，2024年1月5日（环球通讯社）--Prime Medicine，Inc.（纳斯达克：PRME），一家致力于提供新型差异化一次性治疗性基因疗法的生物技术公司，今天宣布任命医学博士艾伦·雷恩为公司首席财务官，自2024年1月17日起生效。

A seasoned financial executive with over twenty years’ experience in the biotechnology industry, Dr. Reine will be responsible for the company’s financing strategy and investor relations, and will oversee all financial operations as Prime Medicine begins its transition into a clinical company. “I am delighted to welcome Allan to Prime Medicine.

雷恩博士是一位经验丰富的财务主管，在生物技术行业拥有20多年的经验，他将负责公司的融资策略和投资者关系，并将在Prime Medicine开始向临床公司过渡时监督所有财务运营。“我很高兴欢迎艾伦加入Prime Medicine。

He brings tremendous financial, operational and leadership experience in the life sciences space, as well as a proven track record developing and implementing multi-pronged strategies to finance a diverse pipeline and broad platform,” said Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine.

他在生命科学领域拥有丰富的财务、运营和领导经验，并拥有制定和实施多管齐下战略的良好记录，为多样化的渠道和广泛的平台提供资金，”Prime Medicine总裁兼首席执行官Keith Gottesdiener医学博士说。

“We look forward to his many contributions as we advance our lead programs toward the clinic, leverage the modularity of our Prime Editing technology to address a wide range of diseases and, ultimately, execute on our vision of delivering the promise of one-time, curative genetic therapies to patients worldwide.” Prior to joining Prime Medicine, Dr.

“我们期待着他的许多贡献，因为我们将领先项目推向临床，利用Prime编辑技术的模块化来解决广泛的疾病，并最终实现我们的愿景，为全世界的患者提供一次性治疗性基因疗法的承诺。”加入Prime Medicine之前，Dr。

Reine was Chief Financial Officer at Foghorn Therapeutics and, before that, at Pieris Pharmaceuticals. Dr. Reine also serves as Chairman of the Board of ONK Therapeutics. Previously, Dr. Reine managed various healthcare portfolios primarily focused on biotechnology and pharmaceutical companies at Lombard Odier Asset Management, Citi Principal Strategies, SAC Capital, Trivium Capital and Alexandra Investment Management.

Reine曾任Foghorn Therapeutics的首席财务官，此前曾任Pieris Pharmaceuticals的首席财务官。Reine博士还担任ONK Therapeutics董事会主席。此前，雷恩博士管理着各种医疗保健投资组合，主要集中在伦巴第奥迪亚资产管理公司（Lombard Odier Asset Management）、花旗主要策略公司（Citi Principal Strategies）、SAC Capital、Trivium Capital和Alexandra Investment Management）的生物技术和制药公司。

He started his career a.

他开始了他的职业生涯。